Pharmacological strategies for hemodialysis arteriovenous fistula and graft patency: an access-stratified systematic review and network meta-analysis.
Shang Yiwei Y, Zheng Danna D, He Ran R, Luo Qikai Q et al.
Pharmacological therapies target different stages of hemodialysis access failure. We compared treatments separately in arteriovenous fistulas (AVFs) and grafts (AVGs), accounting for differences in outcomes and follow-up. This PROSPERO-registered review (CRD420261411441) followed PRISMA 2020 and PRISMA-NMA guidance. PubMed, Embase, CENTRAL/Cochrane records, and ClinicalTrials.gov were searched through May 31, 2026. Two reviewers independently screened records, extracted data, and assessed RoB 2. Separate random-effects frequentist network meta-analyses were supplemented by time-restricted analyses and exploratory follow-up meta-regression. Among 1,557 records, 31 reports were included; 23 trial datasets contributed to the primary analyses (15 AVF and 8 AVG). In AVFs, ticlopidine (OR, 0.37; 95% CI, 0.18-0.76) and clopidogrel (0.49; 0.24-0.97) may reduce predominantly early access failure (low certainty); estimates remained favorable at follow-up of 8 weeks or less. Larger single-trial effects for heparin plus anisodamine and clopidogrel plus a prostacyclin analog were very uncertain. Fish oil showed no clear AVF benefit. In AVGs, apixaban may reduce thrombosis (0.12; 0.03-0.41; low certainty), but its interval widened to 0.007-1.94 in the approximately 12-month subset. The aspirin estimate (3.35; 1.21-9.27) was very uncertain and imprecise under timing restrictions. Ticlopidine and clopidogrel may reduce early AVF failure without established improvement in functional maturation. AVG apixaban findings require confirmation, and the effect of aspirin remains very uncertain. Interpretation depends on the clinical outcome, follow-up, and bleeding risk.